Gelonghui, Feb. 18 | Puli Pharmaceuticals (300630.SZ) announced that the company recently received a marketing license for lacosamide injections issued by the US Food and Drug Administration (“FDA”). Indications are (1) treatment of partial seizure seizures in patients aged 4 years and above; (2) adjuvant treatment of primary generalized tonic-clonic seizures in patients aged 4 and above.
Lacosamide is one of a series of functional amino acids that have been shown to have anticonvulsant effects in different preclinical models and clinical studies. In vitro electrophysiological studies have shown that lacosamide selectively increases slow inactivation of voltage-gated sodium channels, leading to a stabilizing effect on hyperexcited neuronal cell membranes.